Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor
Arthur Kavanaugh, Philip J. Mease, Juan J. Gómez‐Reino, et al.
Annals of the Rheumatic Diseases (2014) Vol. 73, Iss. 6, pp. 1020-1026
Open Access | Times Cited: 425

Showing 1-25 of 425 citing articles:

Psoriatic Arthritis
Christopher T. Ritchlin, Robert A. Colbert, Dafna D. Gladman
New England Journal of Medicine (2017) Vol. 376, Iss. 10, pp. 957-970
Closed Access | Times Cited: 1095
European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
Laure Gossec, Josef S Smolen, Sofía Ramiro, et al.
Annals of the Rheumatic Diseases (2015) Vol. 75, Iss. 3, pp. 499-510
Open Access | Times Cited: 885
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates, Arthur Kavanaugh, Philip J. Mease, et al.
Arthritis & Rheumatology (2016) Vol. 68, Iss. 5, pp. 1060-1071
Open Access | Times Cited: 880
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 700.1-712
Open Access | Times Cited: 834
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes, Philip J. Mease, Bruce Kirkham, et al.
The Lancet (2015) Vol. 386, Iss. 9999, pp. 1137-1146
Open Access | Times Cited: 788
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Kim Papp, Kristian Reich, Craig L. Leonardi, et al.
Journal of the American Academy of Dermatology (2015) Vol. 73, Iss. 1, pp. 37-49
Open Access | Times Cited: 598
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis Care & Research (2018) Vol. 71, Iss. 1, pp. 2-29
Open Access | Times Cited: 437
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
C. Paul, Jennifer Clay Cather, Melinda Gooderham, et al.
British Journal of Dermatology (2015) Vol. 173, Iss. 6, pp. 1387-1399
Open Access | Times Cited: 436
2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
Jasvinder A. Singh, Gordon Guyatt, Alexis Ogdie, et al.
Arthritis & Rheumatology (2018) Vol. 71, Iss. 1, pp. 5-32
Open Access | Times Cited: 398
Psoriasis: Which therapy for which patient
Shivani B. Kaushik, Mark Lebwohl
Journal of the American Academy of Dermatology (2018) Vol. 80, Iss. 1, pp. 27-40
Closed Access | Times Cited: 322
Psoriatic arthritis: state of the art review
Laura C. Coates, Philip Helliwell
Clinical Medicine (2017) Vol. 17, Iss. 1, pp. 65-70
Open Access | Times Cited: 273
The cAMP Pathway as Therapeutic Target in Autoimmune and Inflammatory Diseases
Verena Raker, Christian Becker, Kerstin Steinbrink
Frontiers in Immunology (2016) Vol. 7
Open Access | Times Cited: 271
Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)
Christopher J Edwards, Francisco J. Blanco, Jeffrey Crowley, et al.
Annals of the Rheumatic Diseases (2016) Vol. 75, Iss. 6, pp. 1065-1073
Open Access | Times Cited: 261
Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
Robert S. Wallis, Markus Maeurer, Peter Mwaba, et al.
The Lancet Infectious Diseases (2016) Vol. 16, Iss. 4, pp. e34-e46
Open Access | Times Cited: 248
Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
Claudia Schinocca, Chiara Rizzo, Serena Fasano, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 245
Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities
Christian Dejaco, Elisabeth Brouwer, Justin C. Mason, et al.
Nature Reviews Rheumatology (2017) Vol. 13, Iss. 10, pp. 578-592
Closed Access | Times Cited: 200
A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial
Maurizio Cutolo, Gary E. Myerson, Roy Fleischmann, et al.
The Journal of Rheumatology (2016) Vol. 43, Iss. 9, pp. 1724-1734
Closed Access | Times Cited: 199
Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis
Philip J. Mease, Alice B. Gottlieb, Désirée van der Heijde, et al.
Annals of the Rheumatic Diseases (2017) Vol. 76, Iss. 9, pp. 1550-1558
Open Access | Times Cited: 196
Psoriatic arthritis
Oliver FitzGerald, Alexis Ogdie, Vinod Chandran, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 194
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlled trial (LIBERATE)
Kristian Reich, Melinda Gooderham, L. Green, et al.
Journal of the European Academy of Dermatology and Venereology (2016) Vol. 31, Iss. 3, pp. 507-517
Open Access | Times Cited: 182
Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis
Andreas Kerschbaumer, Josef S Smolen, Maxime Dougados, et al.
Annals of the Rheumatic Diseases (2020) Vol. 79, Iss. 6, pp. 778-786
Open Access | Times Cited: 169
Signaling pathways and targeted therapies for psoriasis
Jia Guo, H. Zhang, Wenrui Lin, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 132
Psoriatic arthritis from a mechanistic perspective
Georg Schett, Proton Rahman, Christopher T. Ritchlin, et al.
Nature Reviews Rheumatology (2022) Vol. 18, Iss. 6, pp. 311-325
Closed Access | Times Cited: 94
Psoriatic Arthritis: Pathogenesis and Targeted Therapies
Ana Belén Azuaga, Julio Ramírez, Juan D. Cañete
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4901-4901
Open Access | Times Cited: 76
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
Yuxiong Jiang, Youdong Chen, Qian Yu, et al.
BioDrugs (2023) Vol. 37, Iss. 1, pp. 35-55
Open Access | Times Cited: 56
Page 1 - Next Page

Scroll to top